Inozyme Pharma Inc. (INZY)
Inozyme Pharma Statistics
Share Statistics
Inozyme Pharma has 64.24M shares outstanding. The number of shares has increased by 4% in one year.
| Shares Outstanding | 64.24M |
| Shares Change (YoY) | 4% |
| Shares Change (QoQ) | 2.4% |
| Owned by Institutions (%) | 86.27% |
| Shares Floating | 43.56M |
| Failed to Deliver (FTD) Shares | 10.21K |
| FTD / Avg. Volume | 1.27% |
Short Selling Information
The latest short interest is 3.85M, so 6% of the outstanding shares have been sold short.
| Short Interest | 3.85M |
| Short % of Shares Out | 6% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 5.41 |
Valuation Ratios
The PE ratio is -3.1 and the forward PE ratio is -1.01. Inozyme Pharma's PEG ratio is 0.15.
| PE Ratio | -3.1 |
| Forward PE | -1.01 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 1.57 |
| P/FCF Ratio | -3.11 |
| PEG Ratio | 0.15 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Inozyme Pharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.36, with a Debt / Equity ratio of 0.33.
| Current Ratio | 13.36 |
| Quick Ratio | 13.36 |
| Debt / Equity | 0.33 |
| Total Debt / Capitalization | 24.91 |
| Cash Flow / Debt | -1.52 |
| Interest Coverage | -22.7 |
Financial Efficiency
Return on equity (ROE) is -0.51% and return on capital (ROIC) is -40.44%.
| Return on Equity (ROE) | -0.51% |
| Return on Assets (ROA) | -0.35% |
| Return on Capital (ROIC) | -40.44% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.21M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -81.68% in the last 52 weeks. The beta is 1.29, so Inozyme Pharma's price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -81.68% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 3.95 |
| Relative Strength Index (RSI) | 30.55 |
| Average Volume (20 Days) | 803.8K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.29M |
| Operating Income | -75.64M |
| Net Income | -71.17M |
| EBITDA | -74.81M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
The company has 34.59M in cash and 46.59M in debt, giving a net cash position of -12M.
| Cash & Cash Equivalents | 34.59M |
| Total Debt | 46.59M |
| Net Cash | -12M |
| Retained Earnings | -285.93M |
| Total Assets | 143.36M |
| Working Capital | 122.59M |
Cash Flow
In the last 12 months, operating cash flow was -70.67M and capital expenditures -298K, giving a free cash flow of -70.97M.
| Operating Cash Flow | -70.67M |
| Capital Expenditures | -298K |
| Free Cash Flow | -70.97M |
| FCF Per Share | -1.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INZY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -114.17% |
| FCF Yield | -92.45% |
Analyst Forecast
The average price target for INZY is $16, which is 1233.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 1233.3% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -3.76 |
| Piotroski F-Score | 2 |